✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Reviewed by Sophie Carter, MPharm — last reviewed 10 May 2026
Quick Answer — Clomid vs Letrozole
Clomid (clomiphene citrate) is a selective estrogen receptor modulator (SERM) — the original ovulation-induction medication, on the market since 1967, FDA-approved for anovulatory infertility. Letrozole (Femara, Letroheal) is a third-generation aromatase inhibitor — originally developed for hormone-receptor-positive breast cancer, now used off-label as the preferred first-line ovulation inducer for polycystic ovary syndrome (PCOS) since the 2014 PPCOS-II trial.
For PCOS-related infertility, modern reproductive-endocrinology guidelines now favor letrozole over Clomid: higher live-birth rate, lower multiple-pregnancy rate, and a thicker endometrium at implantation. For unexplained infertility or non-PCOS anovulation, the two are roughly equivalent. For male HPG-axis support and post-cycle therapy, clomiphene (and its purified isomer enclomiphene) is the preferred molecule.
Mechanism — opposite ends of the estrogen pathway
Both drugs ultimately increase FSH/LH secretion, but they get there by completely different routes:
- Clomiphene binds and blocks estrogen receptors in the hypothalamus. The hypothalamus reads this as “low estrogen,” releases more GnRH, which triggers FSH/LH from the pituitary, which stimulates ovarian follicle growth. Clomiphene’s anti-estrogen action lasts 5–7 days and persists in the body for weeks (long half-life metabolites).
- Letrozole blocks the aromatase enzyme that converts androgens to estrogen — primarily in adipose tissue and the ovary itself. With less estrogen circulating, the hypothalamus releases more GnRH, the same FSH/LH cascade follows. Crucially, letrozole’s half-life is short (~2 days), so the anti-estrogen effect clears before implantation — preserving normal endometrial thickness.
The endometrial-thickness difference is the central reason letrozole has overtaken Clomid for PCOS. Clomid’s prolonged anti-estrogen action thins the endometrium in 15–30% of cycles, hurting implantation. Letrozole doesn’t.
Head-to-head efficacy — PPCOS-II and modern data
The pivotal trial: PPCOS-II (Legro et al., NEJM 2014) randomized 750 PCOS-related infertility patients to letrozole 2.5–7.5 mg or clomiphene 50–150 mg for up to 5 cycles. Results:
| Endpoint (PCOS infertility) | Letrozole | Clomiphene |
|---|---|---|
| Live birth rate per patient (5 cycles) | 27.5% | 19.1% |
| Ovulation rate per cycle | 61.7% | 48.3% |
| Multiple pregnancy rate | 3.4% | 7.4% |
| Endometrial thickness at trigger | ~9 mm (preserved) | ~7 mm (thinned) |
| Hot flashes | 12% | 28% |
| Visual disturbances | Rare | 2–5% |
Translation: in PCOS, letrozole produces ~44% more live births than Clomid while halving the twin rate — a major win because twin pregnancies carry meaningfully higher maternal and neonatal risk. ASRM (American Society for Reproductive Medicine) and ESHRE (European Society) both updated guidelines in 2018 to recommend letrozole as first-line for PCOS-related anovulation.
Research Spotlight — non-PCOS infertility
For non-PCOS unexplained infertility, the AMIGOS trial (NEJM 2015) compared clomiphene, letrozole, and gonadotropins. Live-birth rates were similar between clomiphene and letrozole; gonadotropins produced more pregnancies but at much higher cost and twin-rate. So the “letrozole wins” story is specifically about PCOS — for unexplained infertility the two SERM-vs-AI approaches are roughly equivalent and choice often comes down to side-effect tolerance.
Dosing protocols
Both are dosed as days-3-to-7 (or days-5-to-9) of the menstrual cycle, with monitoring follicle ultrasound and trigger timing.
Clomiphene (Clomid):
- Cycle 1: 50 mg daily × 5 days (days 3–7).
- If no ovulation: increase to 100 mg the next cycle.
- Maximum: 150 mg daily — beyond this the anti-estrogen endometrial effect outweighs benefit.
- Usually paired with mid-cycle ultrasound and an hCG trigger shot (Eutrig HP / HUCOG / ZyHCG) to time ovulation.
- Maximum 6 cumulative cycles (lifetime risk-benefit limit).
Letrozole (Femara, Letroheal):
- Cycle 1: 2.5 mg daily × 5 days (days 3–7).
- If no ovulation: 5 mg the next cycle, then 7.5 mg if needed.
- Maximum: 7.5 mg daily.
- Same ultrasound monitoring + hCG trigger pattern.
- Some clinics now favor 5 mg as first-line PCOS dose based on later studies (Mitwally 2002 and follow-ups).
Side-effect profile — practical comparison
Both drugs are well-tolerated; side effects are typically mild and limited to the 5-day dosing window plus the immediate post-cycle period.
| Side effect | Clomiphene | Letrozole |
|---|---|---|
| Hot flashes | ~28% | ~12% |
| Mood swings | ~15% | ~5% |
| Visual disturbances | 2–5% | Rare |
| Fatigue / dizziness | ~10% | ~10% |
| Endometrial thinning | 15–30% of cycles | Minimal |
| Multiple pregnancy | ~7% | ~3% |
| Ovarian hyperstimulation syndrome (OHSS) | Very rare | Very rare |
Clomiphene’s visual disturbance — typically described as light flashes or after-images — is mild and reversible but is a reason to discontinue and switch to letrozole if it occurs.
Pregnancy contraindication and timing
Both drugs are contraindicated during pregnancy — they’re cycle-day-3-to-7 medications, not luteal-phase medications. Confirmation of pregnancy is required at end of cycle and if positive, the next cycle’s dose is held. Both drugs have short clearance times relative to pregnancy timing — by the time implantation occurs, drug levels are falling, and any teratogenic risk is minimal. Letrozole’s earlier teratogenic-concern reports (Tulandi 2006) have been investigated repeatedly and not confirmed; current consensus is that letrozole is at least as safe as clomiphene for cycle-induction use.
Where male infertility and post-cycle therapy fit in
Clomiphene has a second life beyond female ovulation induction: it’s the standard SERM for restoring the male hypothalamic-pituitary-gonadal (HPG) axis after androgen suppression. Use cases:
- Male infertility / low testosterone: off-label clomiphene 12.5–25 mg daily restores natural testosterone and preserves fertility (vs TRT, which suppresses both LH and spermatogenesis).
- Post-cycle therapy (PCT) after androgen-suppressing peptide cycles: clomiphene 50 mg/day × 4 weeks, sometimes combined with tamoxifen — see PCT Stack.
- Bridge after testosterone replacement: clomiphene 25 mg daily can support endogenous testosterone production while exogenous TRT is being tapered.
Enclomiphene is the purified isomer of clomiphene that retains the SERM-mediated HPG-axis stimulation while removing the “estrogen-agonist” isomer (zuclomiphene) responsible for most of clomiphene’s mood/visual side effects. Enclomisign (enclomiphene) is increasingly preferred for male HPG-axis use because of its cleaner profile.
Common drug-pairing protocols
- PCOS-related infertility: letrozole 2.5–5 mg days 3–7 + ultrasound monitoring + hCG trigger when leading follicle ≥18 mm + timed intercourse or IUI.
- Hypothalamic-pituitary anovulation: clomiphene 50–100 mg + hCG trigger.
- Male HPG-axis restoration: clomiphene or enclomiphene 12.5–25 mg daily, monitor testosterone + LH + estradiol monthly.
- Steroid PCT: clomiphene 50 mg/day for 4 weeks ± tamoxifen 20 mg/day for 4 weeks (Tamoxilon, Tamodex). HCG bridge 500–1500 IU twice weekly may be added — see HCG PCT protocol guide.
Where MedsBase fits
We stock the full SERM and aromatase-inhibitor range:
- Clomiphene (SERM): Clomisign, Clomiford.
- Enclomiphene (purified isomer): Enclomisign.
- Letrozole (aromatase inhibitor): Letroheal.
- HCG trigger / fertility support: HUCOG 10000 IU, ZyHCG HP 10000 IU, Eutrig HP 5000 IU.
- PCT bundle: PCT Stack — Clomisign + Tamoxilon.
- Reconstitution supply: Sterile water for injection.
For full HCG-pathway context, see our HCG Buying Guide 2026.
Who is this for
This guide is for adults using clomiphene or letrozole for ovulation induction (PCOS, anovulation, unexplained infertility), male HPG-axis support, or post-cycle therapy. Ovulation induction should be done with cycle ultrasound monitoring — uncontrolled use multiplies the risk of multiple pregnancy and OHSS. If you’re attempting pregnancy after 12 months without success (or 6 months over age 35), formal reproductive-medicine evaluation is the right next step.
Frequently Asked Questions
Is letrozole better than Clomid for PCOS?
Yes — for PCOS-related infertility, modern guidelines (ASRM 2018, ESHRE 2018) recommend letrozole as first-line based on the PPCOS-II trial. Higher live-birth rate (27.5% vs 19.1%), preserved endometrial thickness, lower twin rate. For non-PCOS unexplained infertility the two are roughly equivalent.
Can I use letrozole for male infertility or PCT?
Letrozole has a niche role for men with high estrogen-to-testosterone ratios, but for general HPG-axis restoration clomiphene (or enclomiphene) is the standard SERM. Letrozole’s aromatase blockade can crash estradiol too low if used aggressively in men, leading to joint pain, low libido, and lipid changes.
Why is enclomiphene preferred over clomiphene in some men?
Clomiphene contains two isomers: enclomiphene (the “clean” SERM) and zuclomiphene (a partial estrogen agonist with a long half-life that drives mood swings, visual disturbances, and gynecomastia in some users). Enclomiphene removes the zuclomiphene fraction — same HPG-axis stimulation, cleaner side-effect profile.
How many cycles of Clomid or letrozole are safe?
Standard advice: maximum 6 cumulative ovulation-induction cycles per patient lifetime. After 6 cycles without conception, escalate to gonadotropins or IVF rather than continuing oral agents — the marginal benefit drops sharply after cycle 6 while the cumulative burden continues.
Does letrozole cause birth defects?
Initial reports (Tulandi 2006) suggested possible cardiac and bone-malformation risk. Subsequent larger studies and meta-analyses (Forman 2007, Tatsumi 2017) have not confirmed an elevated risk. Current consensus: letrozole’s pregnancy-outcome safety is at least as good as clomiphene. ASRM and ESHRE both recommend letrozole as first-line for PCOS infertility.
Can I take both Clomid and letrozole in the same cycle?
Off-label combinations exist (combination protocols for poor responders) but increase OHSS risk and complicate monitoring. Standard practice is to use one agent per cycle, switch the other only if the first fails after 3–4 cycles.
What’s the success rate of ovulation induction overall?
For PCOS with letrozole + 5 cycles + IUI/timed intercourse: ~30–40% live-birth rate. For unexplained infertility: ~15–20% per cycle, cumulative ~50% over 4 cycles. Success drops sharply with maternal age >38 — consider advancing to IVF earlier in this group.
Do I need a doctor to prescribe these for ovulation induction?
Strongly recommended — ovulation induction needs cycle ultrasound monitoring to time the trigger, count developing follicles (multiple-pregnancy risk), and detect over-response (OHSS). Self-treating without monitoring multiplies risks for both mother and offspring.
Can clomiphene help me get pregnant if I’m ovulating normally?
Marginally for unexplained infertility — clomiphene + IUI cycles produce ~10–15% pregnancy per cycle in normal-ovulating women with unexplained infertility. The benefit is mostly from cycle synchronization with insemination, not from inducing additional ovulation. Letrozole performs similarly in this setting.
Are Clomid and letrozole expensive?
WHO-GMP-certified clomiphene generic (Clomisign, Clomiford): $20–40 per 5-day cycle. Enclomisign: $40–80. Letroheal (letrozole 2.5 mg): $30–60 per cycle. US brand prices for Femara and Clomid run 5–10× higher.
🔒 Discreet billing — statement shows your crypto-payment processor (a regulated card-payment processor), never “MedsBase”
🌍 Worldwide Shipping — discreet plain envelope, no pharmacy branding
🛡️ Reshipment Assurance — every order covered
✅ Genuine WHO-GMP-certified manufacturer stock — same molecules as US/EU brand at fraction of the cost
💳 Credit-card payment guide — how the on-ramp works
📦 Every MedsBase order is covered by our Reshipment Assurance Policy — if your parcel doesn’t arrive within 20 business days, we reship free.
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.